Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Avicanna Inc AVCNF


Primary Symbol: T.AVCN

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including... see more

TSX:AVCN - Post Discussion

Avicanna Inc > Webinar w $AVCN CEO Aras Azadian - Tue Dec 14 @ 2PM ET
View:
Post by bmreed on Dec 10, 2021 10:24am

Webinar w $AVCN CEO Aras Azadian - Tue Dec 14 @ 2PM ET

Webinar - Avicanna (AVCN) w/ Aras Azadian CEO

Tue, Dec 14 at 2pm ET / 11am PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/8116390862981/WN_FIGVx58-S0-tI66_CUEXbQ

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities